Navamedic ASA Financial report for Q2 2012
(Thomson Reuters ONE) -
Navamedic's second quarter 2012 revenues saw a 25 per cent growth over the same
period last year. Revenues were NOK 22.7 million compared to NOK 18.2 million in
2011. Nearly all revenues were generated by the Vitaflo business area, which
experienced yet another all time high quarter.
EBITDA for the first quarter reached NOK 0.4 million, compared to NOK -1.1
million in the same period of 2011.
+-------------------+---------+---------+----------+----------+---------+
| (in NOK '000) | Q2 2012 | Q2 2011 | YTD 2012 | YTD 2011 | FY 2011 |
+-------------------+---------+---------+----------+----------+---------+
| Revenues | 22 701 | 18 190 | 43 289 | 34 967 | 71 299 |
| | | | | | |
| Gross Profit | 9 212 | 7 154 | 17 477 | 13 826 | 29 272 |
| | | | | | |
| Gross margin | 41 % | 39 % | 40 % | 40 % | 41 % |
| | | | | | |
| | | | | | |
| | | | | | |
| EBITDA | 437 | -1 096 | 495 | -2 078 | -2 639 |
| | | | | | |
| | | | | | |
| | | | | | |
| EBIT | -1 121 | -2 807 | -2 621 | -5 475 | -9 359 |
+-------------------+---------+---------+----------+----------+---------+
For further information, please call Olof Milveden, CEO, telephone
+46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company. Through its
subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of
nutrition and pharmaceutical products in the Nordic markets. Navamedic is
currently building up a generic pharmaceutical business for the Nordic, Dutch
and Belgian markets based on its partnership with Aspen Healthcare of South
Africa.
This information is subject of the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.
The full report with tables and the presentation can be downloaded from
the following links:
Navamedic ASA Q2 2012 report:
http://hugin.info/136020/R/1635755/525667.pdf
Navamedic ASA Q2 2012 presentation:
http://hugin.info/136020/R/1635755/525668.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Navamedic ASA via Thomson Reuters ONE
[HUG#1635755]
Unternehmensinformation / Kurzprofil:
Datum: 23.08.2012 - 19:14 Uhr
Sprache: Deutsch
News-ID 177268
Anzahl Zeichen: 3393
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Navamedic ASA Financial report for Q2 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
